Cargando…

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

This comparative effectiveness study assesses the numbers needed to treat in targeted trials of agents for newly diagnosed ovarian cancer.

Detalles Bibliográficos
Autores principales:	Bartoletti, Michele, Pignata, Sandro, Lorusso, Domenica, Perrone, Francesco, Zara, Diego, Puglisi, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719047/ https://www.ncbi.nlm.nih.gov/pubmed/36459141 http://dx.doi.org/10.1001/jamanetworkopen.2022.45077

Ejemplares similares

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices
por: Bartoletti, M., et al.
Publicado: (2021)

Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors
por: De Giorgi, Ugo, et al.
Publicado: (2019)

Number needed to treat and cost-effectiveness in the prevention of ventilator-associated pneumonia
por: Wyncoll, Duncan, et al.
Publicado: (2012)

The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
por: Dall’Acqua, Alessandra, et al.
Publicado: (2021)

Fertility sparing surgery in early stage epithelial ovarian cancer
por: Ditto, Antonino, et al.
Publicado: (2014)

Reduction in number to treat versus number needed to treat
por: Zhang, Chenyang, et al.
Publicado: (2021)

Number needed to treat for subglottic secretion drainage technology as a ventilator-associated pneumonia prevention strategy
por: Kelley, Scott D
Publicado: (2012)

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Self-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH)(2) NS) for Ovarian Cancer Therapy
por: Adeel, Muhammad, et al.
Publicado: (2021)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Bartoletti, Michele, et al.
Publicado: (2020)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
por: Azzalini, Eros, et al.
Publicado: (2022)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
por: Maiorano, Brigida Anna, et al.
Publicado: (2021)

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
por: Forlani, Luca, et al.
Publicado: (2023)

A miRNA signature assessing ovarian cancer prognosis
por: Bagnoli, Marina, et al.
Publicado: (2016)

Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
por: Remington, Benjamin C., et al.
Publicado: (2021)

The Holy grail, genes and Number Needed to Treat
por: Herbert, Mel
Publicado: (2007)

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
por: Pignata, S, et al.
Publicado: (2007)

Paediatric Visceral Leishmaniasis in Italy: a ‘One Health’ approach is needed
por: Lorusso, Vincenzo, et al.
Publicado: (2013)

Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
por: Indini, Alice, et al.
Publicado: (2019)

Treatment of recurrent epithelial ovarian cancer
por: Pisano, Carmela, et al.
Publicado: (2009)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Pooling data for Number Needed to Treat: no problems for apples
por: Moore, R Andrew, et al.
Publicado: (2002)

Meta-analysis, Simpson's paradox, and the number needed to treat
por: Altman, Douglas G, et al.
Publicado: (2002)

Number needed to treat (NNT) in clinical literature: an appraisal
por: Mendes, Diogo, et al.
Publicado: (2017)

Number Needed to Treat in Multiple Sclerosis Clinical Trials
por: Okwuokenye, Macaulay, et al.
Publicado: (2017)

COVID-19 vaccines: effectiveness and number needed to treat
por: Correia, Luis C L, et al.
Publicado: (2021)

Commentary: Coronary revascularization therapies and number needed to treat
por: Dimagli, Arnaldo, et al.
Publicado: (2022)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
por: Lorusso, Domenica, et al.
Publicado: (2018)

Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups
por: Greggi, Stefano, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fbnbnelu1mnq2vs1cdsdokh48d